Do you want to read an article? Please log in or register.
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial
Genitourinary Cancer
Related content
Genitourinary Cancer
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial
Eur Urol
Grimm MO, Smith M, Hussain M, Saad F, Fizazi K, Littleton N, Paracha N, Srinivasan S, Verholen F, Tombal B
doi: 10.1016/j.eururo.2025.05.037
Genitourinary Cancer
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
Lancet Oncol
Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW, STAMPEDE investigators
doi: 10.1016/S1470-2045(25)00231-1
Genitourinary Cancer
A randomized Phase 3 trial of Metformin in patients initiating androgen deprivation therapy as PRevention and Intervention of MEtabolic syndrome: The PRIME Study
J Urol
Eigl BJ, Elangovan A, Ghosh S, Kim JO, Thoms J, Bouchard M, Peacock M, Fleshner N, Campbell H, Vigneault E, Vincent F, So A, Cury F, Quon H, Carlson R, Lambert C, Klotz L, Chi K, Brundage M, Pollak M, Rebane L, Chiu L, Courneya KS, Usmani N
doi: 10.1097/JU.0000000000004695
Genitourinary Cancer
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study
Eur J Cancer
Ong M, Suzuki H, Smith M, Tombal B, Hussain M, Saad F, Fizazi K, Verholen F, Pham H, Srinivasan S, Lalani AA
doi: 10.1016/j.ejca.2026.116264
RECOMMENDED
Breast Cancer
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial
★ 2
Recommended by
Dr Andreas Müller, Faculty Member
Lancet Oncol
Saito M, Iihara H, Shimokawa M, Udagawa R, Tsuneizumi M, Futamura M, Ishikawa Y, Ogata H, Bando H, Shima H, Hosoya K, Mukohara T, Tanaka K, Ikuta T, Kawate T, Ishida K, Nakai K, Uomori T, Kutomi G, Ozeki R, Yanagisawa N
doi: 10.1016/S1470-2045(25)00233-5
Multiple Myeloma (MM)
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
Lancet Oncol
Manier S, Lambert J, Hulin C, Macro M, Laribi K, Araujo C, Pica GM, Touzeau C, Godmer P, Slama B, Karlin L, Orsini Piocelle F, Dib M, Sanhes L, Morel P, El Yamani A, Tiab M, Tabrizi R, Richez V, Garderet L, Royer B, Bareau B, Mariette C, Fleck E, Robu D, Calmettes C, Rigaudeau S, Demarquette H, Frenzel L, Decaux O, Mohty M, Arnulf B, Bigot N, Perrot A, Corre J, Mary JY, Avet-Loiseau H, Moreau P, Leleu X, Facon T
doi: 10.1016/S1470-2045(25)00280-3
Genitourinary Cancer
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
Ann Oncol
Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Fleming M, Haas T, Ghebremariam S, Kreisl TN, Rajagopalan S, Sartor O, Morris MJ, PSMAfore Investigators
doi: 10.1016/j.annonc.2025.07.003
Non-Malignant Blood Disorders
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial
Am J Hematol
Cooper N, Broome CM, Miyakawa Y, McDonald V, Al-Samkari H, Khelif A, Cataland SR, Barcellini W, Yang R, Mei H, Matthijssens F, Hultberg A, Ciurlia G, Gandini D, Ayguasanosa J, De Beuf K, Pastouret S, Ghanima W, Rodeghiero F, Bussel JB, ADVANCE SC Investigator Trial Group
doi: 10.1002/ajh.70303
Non-Malignant Blood Disorders
Efficacy and Safety of Marstacimab Prophylaxis in Hemophilia A/B With Inhibitors: Results from the Phase 3 BASIS Trial
Blood
Matino D, Acharya S, Taylor CT, Sun P, Agathon D, Raje S, Gould T, Palladino A, Mahlangu J
doi: 10.1182/blood.2025031065